Hunan Siweikang Therapeutic

Hunan Siweikang Therapeutic is a clinical-stage biotechnology company based in Changsha, China, dedicated to the research and development of advanced biological products. The company leverages two core technology platforms: a proprietary mRNA technology platform for vaccines and therapeutics, and a cell therapy platform focused on CAR-T treatments. Its lead candidate, SWK-001, is a CAR-T cell therapy targeting CD19 for the treatment of B-cell malignancies. Siweikang is also actively developing mRNA-based vaccines for infectious diseases and other oncology indications. The company aims to provide innovative and affordable precision medicine solutions to address unmet medical needs.